Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 1/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 10/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19839523 | 0.94 | ILK (0.68) | ILKEPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL9100491 | 0.91 | ILK (0.56) | ILKEPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL9102404 | 0.91 | ILK (0.55) | ILKEPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL17077257 | 0.89 | ILK (0.66) | ILKEPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL17077256 | 0.87 | ILK (0.64) | ILKEPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL17077261 | 0.87 | ILK (0.64) | ILKEPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL15560693 | 0.87 | ILK (0.74) | ILKEPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL23645917 | 0.87 | ILK (0.66) | ILKEPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL17077259 | 0.87 | ILK (0.66) | ILKEPHX2PTGS2AKR1C3ALOX5 | |
| SCHEMBL17077279 | 0.87 | ILK (0.66) | ILKEPHX2PTGS2AKR1C3ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2642856-B1 | INTEGRIN-LINKED KINASE INHIBITORS | UNIV OHIO STATE RES FOUND (US) | 2017-07-19 | — | — | EP | disclosed |
| US-8658647-B2 | Integrin-linked kinase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120142702-A1 | INTEGRIN-LINKED KINASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142702-A1 | INTEGRIN-LINKED KINASE INHIBITORS | PTK2, ITGB1, ITGB2 | ILK 8/4885EPHX2 3969/4885PTGS2 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.